636 related articles for article (PubMed ID: 32111180)
1. Multiple m
Qu N; Qin S; Zhang X; Bo X; Liu Z; Tan C; Wen G; Jiang H
BMC Cancer; 2020 Feb; 20(1):165. PubMed ID: 32111180
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma.
Wu X; Zhang X; Tao L; Dai X; Chen P
Biomed Res Int; 2020; 2020():2053902. PubMed ID: 32733931
[TBL] [Abstract][Full Text] [Related]
3. The Cancer Genome Atlas (TCGA) based m
Liu J; Sun G; Pan S; Qin M; Ouyang R; Li Z; Huang J
Bioengineered; 2020 Dec; 11(1):759-768. PubMed ID: 32631107
[TBL] [Abstract][Full Text] [Related]
4. m
Li W; Liu J; Ma Z; Zhai X; Cheng B; Zhao H
Dis Markers; 2021; 2021():8859590. PubMed ID: 34234878
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
6. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
7. Identification of METTL3 as an Adverse Prognostic Biomarker in Hepatocellular Carcinoma.
Liu GM; Zeng HD; Zhang CY; Xu JW
Dig Dis Sci; 2021 Apr; 66(4):1110-1126. PubMed ID: 32333311
[TBL] [Abstract][Full Text] [Related]
8. Identification of three m6A-related mRNAs signature and risk score for the prognostication of hepatocellular carcinoma.
Li Z; Li F; Peng Y; Fang J; Zhou J
Cancer Med; 2020 Mar; 9(5):1877-1889. PubMed ID: 31943856
[TBL] [Abstract][Full Text] [Related]
9. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma.
Deng M; Fang L; Li SH; Zhao RC; Mei J; Zou JW; Wei W; Guo RP
Mutagenesis; 2021 Oct; 36(5):369-379. PubMed ID: 34467992
[TBL] [Abstract][Full Text] [Related]
10. Analysis of m6A RNA Methylation-Related Genes in Liver Hepatocellular Carcinoma and Their Correlation with Survival.
Li Y; Qi D; Zhu B; Ye X
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540684
[TBL] [Abstract][Full Text] [Related]
11. Identification and Validation of the N6-Methyladenosine RNA Methylation Regulator YTHDF1 as a Novel Prognostic Marker and Potential Target for Hepatocellular Carcinoma.
Bian S; Ni W; Zhu M; Song Q; Zhang J; Ni R; Zheng W
Front Mol Biosci; 2020; 7():604766. PubMed ID: 33363211
[No Abstract] [Full Text] [Related]
12. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
Zhang C; Huang S; Zhuang H; Ruan S; Zhou Z; Huang K; Ji F; Ma Z; Hou B; He X
Oncogene; 2020 Jun; 39(23):4507-4518. PubMed ID: 32366907
[TBL] [Abstract][Full Text] [Related]
13. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
14. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α.
Yang N; Wang T; Li Q; Han F; Wang Z; Zhu R; Zhou J
J Cell Physiol; 2021 May; 236(5):3863-3880. PubMed ID: 33305825
[TBL] [Abstract][Full Text] [Related]
15. N6‑methyladenosine RNA methylation regulators participate in malignant progression and have prognostic value in clear cell renal cell carcinoma.
Zheng Z; Mao S; Guo Y; Zhang W; Liu J; Li C; Yao X
Oncol Rep; 2020 May; 43(5):1591-1605. PubMed ID: 32323803
[TBL] [Abstract][Full Text] [Related]
16. m6A-Related Genes Contribute to Poor Prognosis of Hepatocellular Carcinoma.
Zou Y; Jiang G; Xie Y; Li H
Comput Math Methods Med; 2022; 2022():2427987. PubMed ID: 36339682
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a m
Kong W; Li X; Xu H; Gao Y
Biomark Med; 2020 Sep; 14(13):1217-1228. PubMed ID: 33021385
[No Abstract] [Full Text] [Related]
18. The significance of m6A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma.
Fang Q; Chen H
Mol Med; 2020 Jun; 26(1):60. PubMed ID: 32552682
[TBL] [Abstract][Full Text] [Related]
19. N6-methyladenosine methylation-related genes
Wang Y; Li T; Liu H; Liang Y; Wang G; Fu G; Takatsuki M; Qu H; Jing F; Li J; Jiang M
Ann Transl Med; 2022 Dec; 10(24):1398. PubMed ID: 36660669
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Two-m6A RNA Methylation Regulator Risk Signature as an Independent Prognostic Biomarker in Papillary Renal Cell Carcinoma by Bioinformatic Analysis.
Yang F; Zhao G; Ge L; Song Y; Hong K; Zhang H; Liu C; Hong P; Ma L
Biomed Res Int; 2021; 2021():4582082. PubMed ID: 33628782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]